~~<i id='3567D36E26'><strike id='3567D36E26'><tt id='3567D36E26'><pre id='3567D36E26'></pre></tt></strike></i>~~

Home» focus» leisure time

leisure time

author：knowledge 2025-10-04 08:50:48 Page View：467

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why getting cancer drugs just got harder for rural patients
Next article： Sports medicine is finally prioritizing gender equality

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Covid isolation guidance eased by the CDC

ApersonquarantinedathomewithCovid-19looksoutfromherfrontdooronLongIsland,N.Y.JohnMoore/GettyImagesTh

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

AstraZeneca loses challenge to Medicare drug price negotiation

ANDREWYATES/AFPviaGettyImagesWASHINGTON—AfederaljudgeinDelawareonFridayruledagainstAstraZenecainacas